Assessment of xenograft size indicated a significantly higher growth rate for TSC2−/− AML organoids (4.43 fold change), compared to TSC2+/− (3.55 fold change) or TSC2+/+ kidney organoids (3.4 fold change) at Day 14 post-transplantation (Fig. 5c). This evidence concerns the gene TSC2 and acute myeloid leukemia.